MONTE CARLO, Monaco, March 30, 2026 /PRNewswire/ -- EMA Aesthetics (www.emaaesthetics.com), a global aesthetics company focused on regenerative innovation, today announced the scientific unveiling of ...
The majority of atopic dermatitis (AD) patients with hand and/or foot (H&F) involvement experienced clearance over 12 months of treatment with ADBRY(R) (tralokinumab-ldrm)/ADTRALZA(R) (tralokinumab).1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results